文献速递胸部肿瘤

KEYNOTE-189 更新分析:帕博利珠单抗联合培美曲塞铂类一线治疗转移性非鳞非小细胞肺癌

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2020-03-09

KEYNOTE-189 更新分析显示,在转移性非鳞非小细胞肺癌(NSCLC)患者中,帕博利珠单抗联合培美曲塞铂类较安慰剂联合化疗显著改善总生存(OS)和无进展生存(PFS),无论 PD-L1 表达或肝/脑转移状态如何。截至 2018 年 9 月 21 日,中位随访 23.1 个月,联合组中位 OS 为 22.0 个月 vs 10.7 个月(HR 0.56),中位 PFS 为 9.0 个月 vs 4.9 个月(HR 0.48)。安全性可控。

要点

  • 帕博利珠单抗联合培美曲塞铂类一线治疗显著改善转移性非鳞 NSCLC 的 OS 和 PFS。
  • 获益不受 PD-L1 表达水平或肝/脑转移存在与否影响。
  • 联合组 3-5 级不良事件发生率为 71.9%,与对照组 66.8% 相似。

核心结论

  • 一线帕博利珠单抗联合培美曲塞铂类在转移性非鳞 NSCLC 中持续显示显著改善的 OS 和 PFS,无论 PD-L1 表达或肝/脑转移,安全性可控。

研究设计与样本

  • 随机(2:1)双盲 III 期研究,患者接受培美曲塞和铂类联合帕博利珠单抗(n=410)或安慰剂(n=206),每 3 周 4 周期,后续培美曲塞维持联合帕博利珠单抗或安慰剂最多 35 周期。
  • 安慰剂联合组疾病进展患者可交叉接受帕博利珠单抗单药治疗;反应由中心按 RECIST v1.1 评估。

主要发现

  • 截至 2018 年 9 月 21 日(中位随访 23.1 个月),帕博利珠单抗联合组中位 OS 为 22.0 个月(95%CI 19.5-25.2),安慰剂联合组为 10.7 个月(95%CI 8.7-13.6),HR 0.56(95%CI 0.45-0.70)。
  • 中位 PFS 分别为 9.0 个月(95%CI 8.1-9.9)和 4.9 个月(95%CI 4.7-5.5),HR 0.48(95%CI 0.40-0.58)。
  • 中位 PFS-2 分别为 17.0 个月(95%CI 15.1-19.4)和 9.0 个月(95%CI 7.6-10.4),HR 0.49(95%CI 0.40-0.59)。
  • 帕博利珠单抗联合组的 OS 和 PFS 获益无论 PD-L1 表达或肝/脑转移存在与否均被观察到。
  • 3-5 级不良事件发生率在帕博利珠单抗联合组为 71.9%,安慰剂联合组为 66.8%。

临床怎么用

  • 对于既往未治疗的转移性非鳞 NSCLC 患者,可考虑一线帕博利珠单抗联合培美曲塞铂类,无需依据 PD-L1 表达或肝/脑转移状态选择。

局限性

  • 本次更新分析未预设 alpha,P 值未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680). METHODS: Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by central review. No alpha was assigned to this updated analysis. RESULTS: As of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9 (4.7 to 5.5) months, respectively (HR, 0.48; 95% CI, 0.40 to 0.58). Median (95% CI) time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurred first (progression-free-survival-2; PFS-2) was 17.0 (15.1 to 19.4) months and 9.0 (7.6 to 10.4) months, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). OS and PFS benefits with pembrolizumab were observed regardless of PD-L1 expression or presence of liver/brain metastases. Incidence of grade 3-5 adverse events was similar in the pembrolizumab-combination (71.9%) and placebo-combination (66.8%) groups. CONCLUSION: First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020. PMID: 32150489. doi:10.1200/JCO.19.03136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。